Tibulizumab
Based on 1 Customer Validation
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.86%
- CAS. Nr.: 1849636-24-3
- Molecular Weight:201.43 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Isotype
IgG4-kappa-[scFv-heavy-kappa]2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-17A 14 pM (Kd) |
BAFF 60 pM (Kd) |
In Vitro
Tibulizumab (LY 3090106) binds to mouse BAFF with a KD of 340 nM and does not bind to mouse IL-17. Tibulizumab binds to cynomolgus BAFF and cynomolgus IL-17 with KD of 26.8 pM and 19 pM, respectively[1].
In HT-29 cells, Tibulizumab antagonizes the IL-17-induced secretion of CXCL1 in a concentration-dependent manner (IC50 of 2.00 nM). In T1165 cells, Tibulizumab blocks BAFF-induced proliferation in a concentration-dependent manner (IC50 of 0.064 nM). Tibulizumab simultaneously binds and blocks both BAFF and IL-17[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa-[scFv-heavy-kappa]2
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized BAFF/TNFSF13B Protein, Human (CHO, HY-P7003) can bind Tibulizumab. The EC50 for this effect is 36.68 ng/mL. -
Immobilized IL-17A Protein, Human (HEK293, His, HY-P70527) can bind Tibulizumab. The EC50 for this effect is 19.5 ng/mL.
Chemical Information
-
CAS. Nr. 1849636-24-3
-
Appearance Liquid
-
Molecular Weight 201.43 kDa
-
Color Colorless to light yellow
-
SMILES
[Tibulizumab]
-
Synonyms
LY 3090106
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Tibulizumab Related Classifications
HY-P99563 Related Classifications
Powered by Bioz